An observational study in Breast Cancer Invasive, sponsored by Wenjin Yin. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Wenjin Yin · Observational
This is a real-world multicentre study to investigate the association between blood routine parameters combined with clinicopathological characteristics and breast cancer prognosis.
Wenjin Yin is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients were pathologically diagnosed primary invasive breast cancer from October 2013 to December 2023. They had blood routine results.
Exclusion Criteria:
breast cancer patients with baseline blood routine results available
Procedure: blood routine test
blood routine test at baseline
Disease-free survival
Disease-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.
Time frame: From the date of radical surgery until time of event up to 3 years
Recurrence-free survival
Recurrence-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional recurrence, distant recurrence and death from any cause
Time frame: From the date of radical surgery until time of event up to 3 years
Overall survival
Overall survival time is defined as the time from the date of radical surgery until death from any cause until death from any cause
Time frame: From the date of radical surgery until time of event up to 3 years
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wenjin Yin